Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x ~~QUARTERLY~~Quarterly ~~REPORT~~report ~~PURSUANT~~pursuant TOto ~~SECTION~~Section 13 ORor 15(d) OFof ~~THE~~the Securities Exchange Act of 1934

~~SECURITIES~~For ~~EXCHANGE~~the ~~ACT~~quarterly OFperiod ~~1934~~ended June 29, 2003

~~For~~or ~~the quarterly period ended March 30, 2003~~

OR¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 2-85008-NY

SSI Surgical Services, Inc.

(Exact name of registrant as specified in its charter)

New York		11-2621408
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

5776 Hoffner Avenue, Suite 200, Orlando Florida		32822
(Address of principal executive offices)		(Zip Code)

(407) 249-1946

(Registrant’s telephone number, including area code)

None

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ~~x Yes ¨ No~~

~~Indicate~~x ~~by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act) ¨~~ Yes x ¨ No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act)

¨ Yes x No

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding at ~~March~~July 3031, 2003
Common Stock, $.01 Par Value		19,491,216

SSI Surgical Services, Inc.

Index to Form 10-Q

Three Months and Six Months Ended ~~March~~June 3029, 2003

		Page
Part I	Financial Information:
Part I Financial Information:
	Condensed Consolidated Balance Sheets as of March 30, 2003 and December 29, 2002	3
	Condensed Consolidated Balance Sheets as of June 29, 2003 and December 29, 2002	3
	Condensed Consolidated Statements of Operations for the three months ended March 30, 2003 and March 31, 2002	4
	Condensed Consolidated Statements of Operations for the three months and six months ended June 29, 2003 and June 30, 2002	4
	Condensed Consolidated Statements of Cash Flows for the three months ended March 30, 2003 and March 31, 2002	5
	Condensed Consolidated Statements of Cash Flows for the six months ended June 29, 2003 and June 30, 2002	5
	Notes to the Condensed Consolidated Financial Statements	6
	Management’s Discussion and Analysis of Financial Condition and Results of Operations	67-89
Part II	Other Information:
	Item 4. Controls and Procedures	9
	Item 6. Exhibits and Reports on Form 8-K	8
Part II Other Information:
Signatures		9
	Item 6. Exhibits and Reports on Form 8-K	10
	Signatures	11

SSI Surgical Services, Inc.

Condensed Consolidated Balance Sheets

(Dollars in Thousands)

	March 30, 2003			December 29, 2002
	June 29,2003(Unaudited)			December 29,2002
Assets
Current Assets:
Cash and cash equivalents	$	2724		$	29
Accounts receivable less allowance for doubtful accounts of $415 and $415		7,130			6,912
Accounts receivable less allowance for doubtful accounts of $413 and $415		7,403			6,912
Prepaid expenses and other assets		1,~~805~~371			1,919
Total current assets		8,~~962~~798			8,860
Property and equipment, net		2322,~~714~~886			24,203
Intangibles, net		4,637			4,637
Other assets		~~116~~106			130
Total assets	$	3736,~~429~~427		$	37,830
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	2,~~354~~336		$	2,365
Obligations under capital leases		10—			30
Total current liabilities		2,~~364~~336			2,395
Payable to affiliates		26,~~656~~198			26,544
Total liabilities		2928,~~020~~534			28,939
Shareholders’ equity:
Common Stock	$	195		$	195
Additional paid-in capital		23,019			23,019
Accumulated deficit		(1415,~~805~~321	)		(14,323	)
Total shareholders’ equity		87,~~409~~893			8,891
Total liabilities and shareholders’ equity	$	3736,~~429~~427		$	37,830

See Notes to Condensed Consolidated Statements.

SSI Surgical Services, Inc.

Condensed Consolidated Statements of Operations

(Dollars in Thousands, except per share)

	Three Months Ended
	March 30, 2003			March 31, 2002
Net revenues	$	8,246		$	8,685
Cost of revenues		7,294			7,551
Gross profit		952			1,134
Distribution Expenses		323			386
Selling, general and administrative		1,055			1,078
Loss from operations		(426	)		(330	)
Interest		364			368
Loss before income taxes		(790	)		(698	)
Income tax benefit		(308	)		(272	)
Net loss	$	(482	)	$	(426	)
Loss per common share – basic	$	(.02	)	$	(.02	)
Loss per common share – diluted	$	(.02	)	$	(.02	)
Weighted average common shares		19,491			19,491
Weighted average dilutive common shares		19,491			19,491

(Unaudited)

	Three Months Ended						Six Months Ended
	June 29, 2003			June 30, 2002			June 29, 2003			June 30, 2002

Net revenues	$	8,817		$	8,927		$	17,063		$	17,612
Cost of revenues		7,315			7,550			14,609			15,101

Gross profit		1,502			1,377			2,454			2,511

Distribution Expenses		305			371			628			757
Selling, general and administrative		1,351			1,137			2,406			2,215

Loss from operations		(154	)		(131	)		(580	)		(461	)

Interest		361			388			725			756
Write-down of assets		330			—			330			—

Loss before income taxes		(845	)		(519	)		(1,635	)		(1,217	)

Income tax benefit		(329	)		(202	)		(637	)		(474	)


Net loss	$	(516	)	$	(317	)	$	(998	)		(743	)


Loss per common share – basic	$	(.03	)	$	(.02	)	$	(.05	)		(.04	)


Loss per common share – diluted	$	(.03	)	$	(.02	)	$	(.05	)		(.04	)


Weighted average common shares		19,491			19,491			19,491			19,491


Weighted average dilutive common shares		19,491			19,491			19,491			19,491

See Notes to Condensed Consolidated Statements.

SSI Surgical Services, Inc.

Condensed Consolidated Statements of Cash Flows

(Dollars in Thousands)

	Three Months Ended
	March 30, 2003			March 31, 2002
Cash flows from operating activities:
Net loss	$	(482	)	$	(426	)
Adjustments to reconcile net income to net cash
Provided by (used in) operating activities:
Depreciation		1,448			1,283
Changes in operating assets and liabilities:
Accounts receivable		(218	)		(293	)
Prepaid expenses and other assets		128			(127	)
Accounts payable and accrued liabilities		(11	)		50
Net cash provided by operating activities		865			487
Cash flows for investing activities:
Net purchase of property and equipment		(959	)		(2,351	)
Net cash used by investing activities		(959	)		(2,351	)
Cash flows from financing activities:
Repayments under capital lease obligations		(20	)		(140	)
Net borrowings from affiliates		112			2,021
Net cash provided by financing activities		92			1,881
Increase (decrease) in cash and cash equivalents		(2	)		17
Cash and cash equivalents at beginning of period		29			72
Cash and cash equivalents at end of period	$	27		$	89

(Unaudited)

	Six Months Ended
	June 29, 2003			June 30, 2002

Cash flows from operating activities:
Net loss	$	(998	)	$	(743	)
Adjustments to reconcile net income to net cash
Provided by (used in) operating activities:
Depreciation and amortization		2,952			2,669
Write-down of assets		330			—
Changes in operating assets and liabilities:
Accounts receivable		(491	)		(877	)
Prepaid expenses and other assets		572			(358	)
Accounts payable and accrued liabilities		(29	)		(17	)


Net cash provided by operating activities		2,336			674


Cash flows for investing activities:
Net purchase of property and equipment		(1,965	)		(3,931	)


Net cash used by investing activities		(1,965	)		(3,931	)


Cash flows from financing activities:
Repayments under capital lease obligations		(30	)		(260	)
Net borrowings from affiliates		(346	)		3,490


Net cash provided by financing activities		(376	)		3,230


Increase (decrease) in cash and cash equivalents		(5	)		(27	)

Cash and cash equivalents at beginning of period		29			72


Cash and cash equivalents at end of period	$	24		$	45

See Notes to Condensed Consolidated Statements.

SSI Surgical Services, Inc.

Notes to the Condensed Consolidated Financial Statements

NOTE 1

The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by generally accepted accounting principles for complete financial statements are not included herein. The condensed statements should be read in conjunction with the financial statements and notes thereto included in the latest Form 10K of SSI Surgical Services, Inc. (the “Company”). In the Company’s opinion, all adjustments necessary for a fair presentation of these condensed statements have been included and are of a normal and recurring nature.

NOTE 2

Basic earnings per share are computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed in a similar manner except that the weighted average number of common shares is increased for dilutive securities. Potentially dilutive securities have been excluded from the computation of diluted earnings per share for the three and six months ended ~~March~~June 3029, 2003 and ~~March~~June 3130, 2002, since the results would be antidilutive. The securities excluded at ~~March~~June 3029, 2003 consist of aggregate warrants to purchase 1,500,000 shares of common stock and exercisable incentive and non-qualified options to purchase 1,034,170 shares of common stock.

NOTE 3

The ~~Company~~Detroit ~~has~~facility ~~stock-based~~lease ~~compensation~~expires ~~plans~~August ~~that provide~~31, ~~for~~2003. Based on the ~~granting~~low ofsales ~~incentive~~volume and ~~non-qualified~~the ~~options~~impending tolease ~~directors~~expiration, ~~officers~~the ~~and~~Detroit ~~key~~facility ~~employees~~was toshutdown ~~purchase~~in ~~shares~~June of2003. ~~common~~The ~~stock~~carrying atamount ~~the market price~~ of ~~the~~leasehold ~~stock~~improvements onand ~~the~~equipment ~~dates options are granted. No stock~~written-~~based~~off ~~employee~~was ~~compensation~~$161 ~~cost~~and ~~is reflected~~$169, ~~in net loss~~respectively. NoRemaining ~~stock~~severance costs ~~options~~of ~~were~~$97 ~~granted~~related ~~during~~to the ~~three~~closure ~~months~~were ~~ended~~accrued ~~March~~at 30June 27, 2003. ~~and March 31, 2002~~

NOTE 4

In May 2003, the FASB issued Statement No. 150 (FAS 150), “Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity”. FAS 150 establishes standards for how an issuer classifies and measures in its statement of financial position certain financial instruments with characteristics of both liabilities and equity. It requires that an issuer classify a financial instrument that is within its scope as a liability (or an asset in some circumstances) because that financial instrument embodies an obligation of the issuer. This Statement is effective for financial instruments entered into or modified after May 31, 2003, and otherwise is effective at the beginning of the first interim period beginning after June 15, 2003. The Company does not believe adoption of FAS 150 will have a material impact on the results of operations or financial condition of the Company.

NOTE 5

The Company has stock-based compensation plans that provide for the granting of incentive and non-qualified options to directors, officers and key employees to purchase shares of common stock at the market price of the stock on the dates options are granted. No stock-based employee compensation cost is reflected in net loss. Stock options to purchase 40,000 shares were granted during the three and six

months ended June 29, 2003. No stock options were granted during the three or six months ended June 29, 2003 and June 30, 2002. The Company applies the disclosure-only provisions of SFAS 123 and SFAS 148, “Accounting for Stock-Based Compensation – Transition and Disclosure – an Amendment to FASB Statement No. 123,” continuing to measure compensation cost in accordance with APB 25 “Accounting for Stock Issued to Employees”. There would have been no difference between net loss and pro forma net loss had compensation cost been determined based on the fair value at the grant date consistent with the provisions of SFAS 123.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Results of Operations

Revenues decreased $~~439~~110,000 or 5.1.2%, to $8,~~246~~817,000 for the three months ended ~~March~~June 3029, 2003 compared to $8,~~685~~927,000 for the three months ended June 30, 2002. Revenues decreased $549,000 or 3.1%, to $17,063,000 for the six months ended ~~March~~June 3129, 2003 compared to $17,612,000 for the six months ended June 30, 2002. This decrease is attributed to the closure of the Tampa facility in 2002 and a decline in revenue at the offsite reprocessing facilities, partially offset by additional revenues from new endoscopic services customers.

~~Gross~~The gross profit ~~decreased~~margin increased to ~~$952,000 or 11~~17.50% of revenues for the three months ended ~~March~~June 3029, 2003 compared with $115.4% of revenues for the three months ended June 30,~~134~~ 2002. Gross profit increased to 14.4% of revenues for the six months ended June 29,~~000~~ or2003 13compared with 14.13% of revenues for the ~~three~~six months ended ~~March~~June 3130, 2002. This ~~decrease~~increase is ~~attributed~~primarly tothe aresult ~~volume~~of ~~decline~~continued atcost ~~the~~control ~~offsite~~initiatives ~~reprocessing~~and realignment ~~facilities~~of labor resources.

6Distribution costs decreased to $305,000 or 3.5% of revenues for the three months ended June 29, 2003 compared with $371,000 or 4.2% of revenues for the three months ended June 30, 2002. Distribution costs decreased to $628,000 or 3.7% of revenues for the six months ended June 29, 2003 compared with $757,000 or 4.3% of revenues for the six months ended June 30, 2002.The decrease in distribution costs resulted from the closure of the Tampa facility in 2002 and volume decline at the reprocessing facilities.

Selling, general and administrative expenses increased by $214,000 to $1,351,000 for the three months ended June 29, 2003 compared to $1,137,000 for the three months ended June 30, 2002. Selling, general and administrative expenses increased by $191,000 to $2,406,000 for the six months ended June 29, 2003 compared to $2,215,000 for the six months ended June 30, 2002. The increase was primarily the result of increased selling commissions and severance costs associated with the closure of the Detroit reprocessing facility, offset by continued cost control initiatives.

Interest expense decreased by $27,000 to $361,000 for the three months ended June 29, 2003 compared to $388,000 for the three months ended June 30, 2002. Interest expense decreased by $31,000 to $3725000 for the six months ended June 29, 2003 compared to $756,000 for the six months ended June 30, 2002. This decrease was the result of lower interest rates associated with borrowings from affiliates.

~~Distribution costs~~Net ~~decreased~~loss tofor the three months ended June 29, 2003 was $~~323~~516,000 orcompared ~~3.9%~~to ofnet ~~revenues~~loss of $317,000 for the three months ended ~~March~~June 30, ~~2003~~2002. ~~compared~~Net ~~with~~loss for the six months ended June 29, 2003 was $~~386~~998,000 orcompared ~~4.4%~~to net loss of ~~revenues~~$743,000 for the ~~three~~six months ended ~~March~~June 3130, 2002. ~~The~~Basic ~~decrease~~and indiluted ~~distribution~~earnings ~~costs~~per ~~resulted~~share ~~from~~in the ~~closure~~three ofmonths ~~the~~ended ~~Tampa~~June 29, ~~facility~~2003 represented a net loss per share of $.03, compared to a net loss per share of $.02 in the three months ended June 30, 2002. Basic and ~~volume~~diluted ~~decline~~earnings atper share in the ~~reprocessing~~six ~~facilities~~months ended June 29, 2003 represented a net loss per share of $.05, compared to a net loss per share of $.04 in the six months ended June 30, 2002.

Selling, general and administrative expenses decreased by $23,000 to $1,055,000 for the three months ended March 30, 2003 compared to $1,078,000 for the three months ended March 31, 2002. The decrease was primarily the result of continued cost control initiatives offset by increased selling commissions.

Interest expense decreased by $4,000 to $364,000 for the three months ended March 30, 2003 compared to $368,000 for the three months ended March 31, 2002. This decrease was the result of lower interest rates associated with borrowings from affiliates.

Net loss for the three months ended March 30, 2003 was $482,000 compared to net loss of $426,000 for the three months ended March 31, 2002. Basic and diluted earnings per share in the three months ended March 30, 2003 represented a net loss per share of $.02, compared to a net loss per share of $.02 in the three months ended March 31, 2002.

Liquidity and Capital Resources

The Company generated cash flows from operations of $~~865~~2,336,000 in the ~~three~~six months ended ~~March~~June 3029, 2003 compared to $~~487~~674,000 in the ~~three~~ six months ended ~~March~~June 3130, 2002. This increase in cash flows compared to prior year was primarily the result of a reduction in prepaid and other assets.

Capital expenditures totaled $~~959~~1,965,000 in the ~~three~~six months ended ~~March~~June 3029, 2003 compared with $23,~~351~~931,000 in the ~~three~~six months ended ~~March 31~~June 30, 2002. These purchases were principally surgical instruments made to support the Company’s new and existing sales contracts.

The Company plans to purchase additional surgical instruments and linens, as and if required to support the Company’s growth objectives. The Company believes that additional borrowing capacity under the existing loan agreement with Teleflex Incorporated (Teleflex), its majority shareholder, and cash flows from operating activities will provide support for these expenditures.

The Company had ~~$10,000 in obligations under capital leases for equipment and surgical instruments at March 30, 2003. In addition, the Company had~~ borrowings of $2625,~~575~~924,000 outstanding at ~~March~~June 3029, 2003 under a $27,500,000 unsecured revolving loan agreement with Teleflex. The outstanding principal on this credit facility is due and payable on ~~July~~September 3130, 2004. Interest under this agreement is payable at the prevailing Prime rate of PNC Bank, plus 1.25 percent.

The Company believes that the anticipated future cash flow from operations, along with its cash on hand and available funding from its major shareholder will be sufficient to meet working capital requirements during 2003.

Certain Factors That May Affect Future Results

From time to time, information provided by the Company, statements made by its employees or information included in its filings with the Securities Exchange Commission (including this Form 10-Q) may contain statements which are not historical facts, so-called “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995; in particular, statements made relating to the suitability of the Company’s facilities and equipment for future operations and the availability of additional facilities and equipment in the future, and the sufficiency of funds for the Company’s working capital requirements during the next twelve months may be forward looking statements. The Company’s actual future results may differ significantly from those stated in any forward-looking statements. Factors that may cause such differences include, but are not limited to, the ~~factors discussed below. Each of these factors, and others, are discussed from time to time in the Company’s filings with the Securities and Exchange Commission.~~

factors discussed below. Each of these factors, and others, are discussed from time to time in the Company’s filings with the Securities and Exchange Commission.

The Company’s future results are subject to risks and uncertainties. The Company has operated at a loss or small profit for its entire history. The failure of the Company to continue to compete effectively with existing or new competitors could result in price erosion, decreased margins and decreased revenues, any or all of which could have a material adverse effect on the Company’s business, results of operations and financial condition. Approximately 61% of the Company’s healthcare provider customers are currently concentrated in the Northeast Corridor. Any factors affecting this market generally could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company is subject to government regulation in certain aspects of its operations. Changes in such regulations could have a material adverse effect on the Company’s business, results of operations and financial condition.

The Company’s quarterly and annual operating results are affected by a wide variety of factors that could materially and adversely affect revenues and profitability, including: competitive pressures on selling prices and margins; the timing and cancellation of customer orders; the lengthy sales cycle of the Company’s services to healthcare organizations; the Company’s ability to maintain state-of-the-art sterilization facilities and the corresponding timing and amount of capital expenditures, particularly if the Company executes its plan for growth; and the introduction of new services by the Company’s competitors.

Item 4. Controls and Procedures

As of a date within 90 days prior to the filing of this report, our Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures, which included inquiries made to certain other of our employees. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have each concluded that our disclosure controls and procedures provide reasonable assurance that we record, process, summarize and report information required to be disclosed by us in our periodic reports filed under the Securities Exchange Act within the time periods specified by the Security and Exchange Commission’s rules and forms. Subsequent to the date of their evaluation, there have not been any significant changes in our internal controls or in other factors that could significantly affect these controls, including any corrective actions with regard to significant deficiencies and material weaknesses.

PART II OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K

~~(a)~~1. During ~~Reports~~the quarter ended June 29, 2003, the Company filed the following report on Form 8-K.:

NoOn ~~reports~~June 2, 2003 SSI Surgical Services, Inc. filed a report on Form 8-K ~~were~~dated ~~filed~~May ~~during~~21, 2003, to file as an exhibit the ~~quarter~~certifications of the Company’s Chief Executive Officer and Chief Financial Officer required pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

810

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

August 9, 2003 SSI SURGICAL SERVICES, INC.

9By: /s/ Todd Riddell Todd Riddell President and Chief Executive Officer By: /s/ Paul A. D’Alesio Paul A. D’Alesio Treasurer and Chief Financial Officer

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Todd Riddell, Chief Executive Officer and President of SSI Surgical Services, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of SSI Surgical Services, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

6. The registrant’s other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: ~~May~~August 219, 2003

/s/ ~~TODD~~Todd ~~RIDDELL Chief Executive Officer and President~~Riddell

Chief Executive Officer and President

CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Paul A. D’Alesio, Chief Financial Officer and Treasurer of SSI Surgical Services, Inc., certify that:

1. I have reviewed this quarterly report on Form 10-Q of SSI Surgical Services, Inc.;

b) evaluated the effectiveness of the registrant’s disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls; and

Date: ~~May~~August 219, 2003

/s/ ~~PAUL~~Paul A. D’~~ALESIO Chief Financial Officer and Treasurer~~Alesio

12Chief Financial Officer and Treasurer

May 21, 2003

SSI SURGICAL SERVICES, INC.

/s/ TODD RIDDELL

Todd Riddell President and Chief Executive Officer

/s/ PAUL A. D’ALESIO

Paul A. D’Alesio Treasurer and Chief Financial Officer

Filing Compare · SSI SURGICAL SERVICES INC